Cipla's InvaGen Facility Receives NAI Classification from US FDA
Cipla's wholly owned US subsidiary, InvaGen Pharmaceuticals, receives a No Action Indicated classification from the US FDA following an inspection of its Hauppauge manufacturing facility in New York.
No Action Indicated | 18/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy